(Date:9/5/2008)...ert Pathologists Discuss the Latest Developments i...RTHFIELD, Ill., Sept. 5 /PRNewswire-USNewswire/ --...point. Molecular testing and the promise,of person...reated. Digital,slides and other imaging technolog...lege of American Pathologists is taking a leadersh...
(Date:9/5/2008)...hers explain how theoretical ,anti-cloak, could br...pt. 5 (HealthDay News) -- Just in case someone dev...cientists say they know how to uncloak the objects... Optics Express , certain materials underneath an ...o be seen again. , Researchers at Shanghai Jiao...
(Date:9/5/2008)...HINGTON, Sept. 5 /PRNewswire-USNewswire/ -- Speake...y in support of the aims of the "Stand,Up to Cance... "There is not a person in our country who has no...r kills 565,000 Americans annually, and each,year ...ricans must work,together to make eradicating the ...
(Date:9/5/2008)...HINGTON, Sept. 5 /PRNewswire-USNewswire/ -- U.S. c...r relief to Cuban victims of Hurricane,Gustav, whi...s., (http://www.PanAmericanRelief.org ), "Donatio...perately need,after this natural disaster," says M... Initiative at the Pan American Development Founda...
Breaking Medicine News(10 mins):Health News:Leaders in Pathology Meet in San Diego: Sept. 25 - 28, 2008 2Health News:Cuban Disaster Relief Donations Sought in the Wake of Hurricane Gustav 2...earchers from the Columbia University Medical Cent...an affect the gums much earlier than anticipated. ...th and Naomi Berrie Diabetes Center also collabora...e February issue of Diabetes Care. "Our research i...
...ection from the Human Immunodeficiency Virus (HIV)...ding to US based scientists. The disease is report...world since 1981. //The lab tests of the chemical ...s's ability to infect cells, according to BBC News...
... life expectancy across the world is increasing, a...he UK who are in their 30s will live to see their ... the population of centenarians is expected to soa... 1.2 million by 2074 in Britain, according to the ...
... possibility of cavity problems in infants can be ...tment per year. This particular treatment does not...und is directly brushed into the teeth. //The Jour...gs which say that children who did not receive the...
Other Medicine News:Health News:Gum Disease Affects Diabetic Children Earlier Than Anticipated 2(Date:9/5/2008)... SOUTH SAN FRANCISCO, Calif., Sept. 5 /PRNewswi...mpany focused on small molecule LFA-1 inhibitors,t...euticals, Inc. (Nasdaq:,SNSS) today announced SARc...small molecule LFA-1 product candidate for T-cell ...entered into a license agreement providing,SARcode...
(Date:9/4/2008)... SAN MATEO, Calif., Sept. 4 /PRNewswire-FirstCa...y announced that the pivotal clinical study of,Pol...s partner, Chemische,Fabrik KREUSSLER & Co. GmbH (...point and has been submitted to FDA as part of a N...l clinical study, named the EASI (Efficacy and saf...
(Date:9/4/2008)... Pivotal Study Seeks to Enroll 750 Women at More T.... 4 /- QuatRx Pharmaceuticals, a,priv...velopment and,commercialization of compounds to tr...ers, today announced that it has initiated a secon... tablets), the company,s,estrogen-free oral therap...
(Date:9/4/2008)... Data Announcements Remain on Schedule with Two ... Clinical Data Release in November 2008, BRIDGEWA...ceuticals,Inc., a specialty pharmaceutical compan...etabolic disease, today announced the appointment ... of directors., Peter Garrambone,s career include...
Breaking Medicine Technology:SARcode and Sunesis Announce Start of Phase 1 Clinical Trial in Ocular Inflammatory Diseases 2SARcode and Sunesis Announce Start of Phase 1 Clinical Trial in Ocular Inflammatory Diseases 3338 Patient Pivotal Trial Demonstrates Safety and Effectiveness of Polidocanol Sclerotherapy Product for Varicose Vein Treatment 2338 Patient Pivotal Trial Demonstrates Safety and Effectiveness of Polidocanol Sclerotherapy Product for Varicose Vein Treatment 3338 Patient Pivotal Trial Demonstrates Safety and Effectiveness of Polidocanol Sclerotherapy Product for Varicose Vein Treatment 4338 Patient Pivotal Trial Demonstrates Safety and Effectiveness of Polidocanol Sclerotherapy Product for Varicose Vein Treatment 5QuatRx Initiates Second Phase 3 Study of Ophena(TM) (Ospemifene Tablets) in Women With Postmenopausal Vaginal Syndrome 2QuatRx Initiates Second Phase 3 Study of Ophena(TM) (Ospemifene Tablets) in Women With Postmenopausal Vaginal Syndrome 3Aegerion Pharmaceuticals, Inc. adds Peter Garrambone to Board of Directors, Secures Additional Capital for Clinical Trials 2Chemotherapy with gemcitabine delays progression of operable pancreatic cancer 2181 1Chemotherapy with gemcitabine delays progression of operable pancreatic cancer 2181 2Susan G Komen for the Cure Partners With the Original Butter Bell 28R 29 Crock Developer 2176 1Susan G Komen for the Cure Partners With the Original Butter Bell 28R 29 Crock Developer 2176 2Kaiser Permanente Study Shows Alcohol Consumption No Matter Beverage Type Linked to Breast Cancer Risk 2172 1Kaiser Permanente Study Shows Alcohol Consumption No Matter Beverage Type Linked to Breast Cancer Risk 2172 2Kaiser Permanente Study Shows Alcohol Consumption No Matter Beverage Type Linked to Breast Cancer Risk 2172 3Kaiser Permanente Study Shows Alcohol Consumption No Matter Beverage Type Linked to Breast Cancer Risk 2172 4Eating AGE Rich Foods Causes Dysfunction Linked to Heart Disease 2168 1Eating AGE Rich Foods Causes Dysfunction Linked to Heart Disease 2168 2...ity of Abstracts Reflects Continued Growth of Eisa...May 31, 2007 /PRNewswire/ -- Eisai,announced today...ut,their oncology pipeline compounds have been acc...Clinical Oncology (ASCO),annual meeting. ASCO take...stracts reveal a growing and diverse oncology clin...
...-(BUSINESS WIRE)--May 31, 2007 - Hemispherx Biopha... engaged in the clinical,development and manufactu...ts, announced today a new scientific report featur...feron-LDO in,combating highly pathogenic avian inf...DO is a low-dose experimental oral formulation,of ...
Other Medicine Technology:Clinical Data on Eisai's Oncology Pipeline to be Presented at ASCO,Annual Meeting 2Clinical Data on Eisai's Oncology Pipeline to be Presented at ASCO,Annual Meeting 3Clinical Data on Eisai's Oncology Pipeline to be Presented at ASCO,Annual Meeting 4Hemispherx Presents Potential Avian Influenza Treatment,Breakthrough at Paris Conference 2Hemispherx Presents Potential Avian Influenza Treatment,Breakthrough at Paris Conference 3Hemispherx Presents Potential Avian Influenza Treatment,Breakthrough at Paris Conference 4Full Handle Laseredge Implant Blade Knife, 6.0 pilot tip. Blade dimension: 16.5 mm x 6.0 mm x 4.2 mm x 2.4 mm.
Full Handle Laseredge Implant Blade Knife, 3.2 mm round tip. Blade dimension: 14.4 mm x 3.2 mm x 3.8 mm x 1.65 mm.
Full Handle Laseredge Implant Blade Knife, 5.2 mm straight. Blade dimension: 16.5 mm x 5.2 mm x 4.2 mm x 1.6 mm.
Full Handle Laseredge Crescent Blade Knife, angled bevel down. Blade tip dimension: 12.7 mm x 2.0 mm x 3.8 mm.
Medicine Products: